Table 1 IAPs and negative prognosis
From: IAPs on the move: role of inhibitors of apoptosis proteins in cell migration
Cancer type | IAPs involved | Detection parameter | References |
|---|---|---|---|
IAPs and negative prognosis | |||
Esophageal squamous cell carcinoma | cIAP1 and cIAP2 | Genomic DNA and RNA (11q21–23 amplicon) | Imoto et al.119 |
SCLC and NSCLC | cIAP1 and cIAP2 | Genomic DNA and Protein (11q21–23 amplicon) | Dai et al.27 |
Hepatocellular carcinoma | cIAP1 | Genomic DNA and RNA (11q21–23 amplicon) | Zender et al.29 |
MALT lymphoma | cIAP2 | RNA (t(11 : 18)(q21 : 21) translocation) | Dierlamm et al.120 |
Acute myeloid leukemia (ALL) | cIAP2 | RNA | Hess et al.33 |
Bladder cancer | XIAP | Protein and RNA | Li et al.36 |
Nuclear cIAP1 | Protein | Che et al.38 | |
Colorectal cancer | XIAP | RNA and protein | Xiang et al.37 |
cIAP2 | Protein | Krajewska et al.35 | |
Breast cancer | Nuclear XIAP | Protein | Zhang et al.39 |
Cervical sqamous cell carcinoma | Nuclear cIAP1 | Protein (resistance to radiotherapy) | Imoto et al.40 |
